Abdel-Hafiz HA, Horwitz KB. Role of epigenetic modifications in luminal breast cancer. Epigenomics. 2015;7(5):847–62. https://doi.org/10.2217/epi.15.10.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr Opin Colloid Interface Sci. 2009;14(1):3–15. https://doi.org/10.1016/j.cocis.2008.01.002.

Article  CAS  Google Scholar 

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cortes J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404. https://doi.org/10.1093/annonc/mdy517.

Article  PubMed  CAS  Google Scholar 

Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Piccart MJ. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 2021;11(11):2796–811. https://doi.org/10.1158/2159-8290.cd-20-1647.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8. https://doi.org/10.1073/pnas.0530291100.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013;8:277–302. https://doi.org/10.1146/annurev-pathol-020712-163923.

Article  PubMed  CAS  Google Scholar 

Anderson KS, Erick TK, Chen M, Daley H, Campbell M, Colson Y, Overmoyer B. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. Breast Cancer Res Treat. 2022;194(1):65–78. https://doi.org/10.1007/s10549-022-06562-y.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Group S-S. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.

Article  PubMed  CAS  Google Scholar 

Apostolidou K, Zografos E, Papatheodoridi MA, Fiste O, Dimopoulos MA, Zagouri F. Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: current perspectives and clinical trials. Breast. 2024;75: 103729. https://doi.org/10.1016/j.breast.2024.103729.

Article  PubMed  PubMed Central  Google Scholar 

Bahrami A, Makiabadi E, Jalali S, Heidari Z, Assadi M, Rashidkhani B. Dietary intake of polyphenols and the risk of breast cancer: a case-control study. Clin Nutr Res. 2021;10(4):330–40. https://doi.org/10.7762/cnr.2021.10.4.330.

Article  PubMed  PubMed Central  Google Scholar 

Bardia A, Cortes J, Bidard FC, Neven P, Garcia-Saenz J, Aftimos P, Kaklamani V. Elacestrant in ER+, HER2- metastatic breast Cancer with ESR1-Mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30(19):4299–309. https://doi.org/10.1158/1078-0432.CCR-24-1073.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Group CS. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19. https://doi.org/10.1056/NEJMoa1113216.

Article  PubMed  CAS  Google Scholar 

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. https://doi.org/10.1056/NEJMoa1109653.

Article  PubMed  CAS  Google Scholar 

Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Kaumaya PTP. Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in Montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors. Clin Cancer Res. 2019;25(12):3495–507. https://doi.org/10.1158/1078-0432.CCR-18-3997.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91–113. https://doi.org/10.1038/s41571-021-00565-2.

Article  PubMed  CAS  Google Scholar 

Boland M, Chourasia A, Macleod K. Mitochondrial dysfunction in cancer. Front Oncol. 2013. https://doi.org/10.3389/fonc.2013.00292.

Article  PubMed  PubMed Central  Google Scholar 

Borah A, Pillai SC, Rochani AK, Palaninathan V, Nakajima Y, Maekawa T, Kumar DS. GANT61 and curcumin-loaded PLGA nanoparticles for GLI1 and PI3K/Akt-mediated inhibition in breast adenocarcinoma. Nanotechnology. 2020;31(18):185102. https://doi.org/10.1088/1361-6528/ab6d20.

Article  PubMed  CAS  Google Scholar 

Breast International Group 1,–, 98, Collaborative G, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57. https://doi.org/10.1056/NEJMoa052258.

Article  Google Scholar 

Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 2014;34(3):1071–7.

PubMed  CAS  Google Scholar 

Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, Kataoka K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815–23. https://doi.org/10.1038/nnano.2011.166.

Article  PubMed  CAS  Google Scholar 

Caino MC, Altieri DC. Molecular pathways: mitochondrial reprogramming in tumor progression and therapy. Clin Cancer Res. 2016;22(3):540–5. https://doi.org/10.1158/1078-0432.ccr-15-0460.

Article  PubMed  CAS  Google Scholar 

Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 1997;14(10):1431–6. https://doi.org/10.1023/a:1012128907225.

Article  PubMed  CAS  Google Scholar 

Cejuela M, Vethencourt A, Pernas S. Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer. Curr Oncol Rep. 2022;24(12):1801–19. https://doi.org/10.1007/s11912-022-01339-4.

Article  PubMed  CAS  Google Scholar 

Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Weinberg RA. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011;108(19):7950–5. https://doi.org/10.1073/pnas.1102454108.

Article  PubMed  PubMed Central  Google Scholar 

Chai C, Wu HH, Abuetabh Y, Sergi C, Leng R. Regulation of the tumor suppressor PTEN in triple-negative breast cancer. Cancer Lett. 2022;527:41–8. https://doi.org/10.1016/j.canlet.2021.12.003.

Article  PubMed  CAS  Google Scholar 

Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69(4):1302–13. https://doi.org/10.1158/0008-5472.CAN-08-2741.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. 2010;121(2):469–77. https://doi.org/10.1007/s10549-009-0593-9.

Article